The Alzheimer’s Disease Sequencing Project (ADSP) is a comprehensive, multi-phase national consortium aimed at understanding the genetic basis of Alzheimer’s disease and related dementias. Here are the key aspects of the ADSP:
https://www.nia.nih.gov/research/dn/alzheimers-disease-sequencing-project-consortia
NO gene expression?!
## Genomic Data
- The ADSP involves whole-genome sequencing (WGS) and whole exome sequencing (WES) of samples from various cohorts.
- **Discovery Phase**: Includes WGS for 584 samples from 113 multiplex families, WES for 5,096 AD cases and 4,965 controls, and WES of an enriched sample set comprising 853 AD cases from multiply affected families and 171 Hispanic controls[2][5][6].
- **Follow-Up Study Phases**: The project has progressed through several phases, including the Discovery Extension Phase, Follow-Up Study Phase, and Follow-Up Study 2.0 Diversity Initiative Phase, which focus on expanding the genetic data to include more diverse populations, such as African Americans, Hispanics, and Asians[1][5].
## Phenotypic Data
- While the primary focus of the ADSP is on genomic data, it also incorporates rich phenotypic data.
- **Clinical and Cognitive Data**: The project includes clinical cognitive data such as memory, language, and executive function scores. However, it does not directly collect neuroimaging data like T1 MRI, Amyloid-beta, or tau PET scans as part of its core sequencing efforts. Instead, these data are often integrated from other studies and consortia[1][3][6].
- **Longitudinal and Autopsy-Confirmed Data**: The project emphasizes the use of well-phenotyped participants with autopsy-confirmed diagnoses and longitudinal data[2][5].
## Harmonized Data
- The ADSP Phenotype Harmonization Consortium (ADSP-PHC) plays a crucial role in harmonizing phenotypic data across different cohorts.
- **ADSP-PHC**: Established to harmonize endophenotype data, including cognitive, imaging, longitudinal clinical, neuropathological, cardiovascular risk, and biomarker data. This harmonization enables modern genomic analyses and generates a perpetually curated and shared legacy dataset[3][6].
## Study Design and Objectives
- The ADSP uses both case-control and family-based study designs.
- **Objectives**: The overarching goals include identifying new genes involved in Alzheimer’s disease, identifying gene alleles contributing to increased risk or protection against the disease, understanding why individuals with known risk factor genes do not develop AD, and identifying potential therapeutic approaches and prevention strategies[1][4][5].
## Diversity and Global Collaboration
- The ADSP places a high priority on racial/ethnic diversity, recognizing that most genetic studies have been conducted in non-Hispanic white populations.
- **Diverse Population Initiative**: The Follow-Up Study 2.0 phase aims to conduct whole-genome sequencing on 18,500 AD cases and 18,500 controls from African American, Hispanic, and Asian populations, ensuring a more diverse sample set[1][2][5].
The ADSP is a collaborative effort involving over 350 investigators from global institutions, funded under several cooperative agreements and research grant awards, and is part of the NIA Alzheimer’s Disease Genetics Portfolio.
Citations:
[1] https://www.nia.nih.gov/research/dn/alzheimers-disease-sequencing-project-consortia
[2] https://dss.niagads.org/studies/sa000001/
[3] https://www.vumc.org/cnt/harmonization-initiative
[4] https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000572.v1.p1
[5] https://adsp.niagads.org/about/adsp-phases/
[6] https://adsp.niagads.org/funded-programs/phenotype-harmonization/
[7] https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13705
[8] https://adsp.niagads.org/adsp-and-affiliates-whole-genome-sequencing-report/